2021 – State Expert Center of the Ministry of Health of Ukraine

Letter to healthcare professionals regarding the medicinal product VIZKEW, solution for injection, 120 mg/ml

29.12.2021 1894

Informational letter to healthcare professionals on updated recommendations for minimizing the risk of intraocular inflammation, retinal vasculitis, and retinal vascular occlusion with the use of VABYSMO. It describes risk factors, monitoring measures, and rules for administering maintenance doses. generated automatically

Fabrazyme®

24.12.2021 2019

Educational materials on home infusion therapy with Fabrazyme® (agalsidase beta) for patients with Fabry disease and healthcare professionals: organization of treatment, preparation, reconstitution, dilution, and administration of the medicinal product, safety assessment, and keeping an infusion log. generated automatically

Gilenya* (fingolimod)

24.12.2021 2162

Set of risk management information materials for physicians, patients and their caregivers on the prevention of pregnancy during treatment with fingolimod, including teratogenic risk, contraception and testing. generated automatically

“Important safety information on the use of IRINOTECAN MEDAC (irinotecan hydrochloride): Drug toxicity in patients with reduced activity of UGT1A1

14.12.2021 1832

Information letter for healthcare professionals on the increased risk of severe neutropenia and diarrhea in patients with reduced UGT1A1 enzyme activity when using irinotecan, as well as on the possibility of reducing the starting dose and performing genotyping. generated automatically

Checklist for a physician prescribing micafungin

09.12.2021 2193

Checklist for physicians prescribing micafungin, developed within the Risk Management Plan to minimize the risk of liver injury. It contains a list of patient conditions that require careful assessment of the benefit/risk balance before prescribing the medicinal product. generated automatically

Information letter for healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders associated with the use of retinoids

09.12.2021 1956

Information letter to healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders with the use of retinoids, prepared on the basis of recommendations of the European Medicines Agency and agreed with the State Expert Center of the MoH of Ukraine. Contains risk minimization measures, including a pregnancy prevention program and recommendations on informing patients. generated automatically

EDUCATIONAL MATERIALS CONTROLFLEX (thiocolchicoside): Information for healthcare professionals on the risk of genotoxicity

09.12.2021 2767

Educational materials for healthcare professionals on the risk of genotoxicity with the use of a thiocolchicoside-based medicinal product: indications, dosage, contraindications, risk minimization measures, and the procedure for reporting adverse reactions. compiled automatically

Letter to healthcare professionals: Important information on the potential risk of genotoxicity with the use of the medicinal product CONTROLFLEX

09.12.2021 2115

Information letter for healthcare professionals on the potential risk of genotoxicity (aneuploidy) with the use of a thiocolchicoside-based medicinal product, contraindications for women of reproductive age and the procedure for reporting adverse reactions. generated automatically

Important information on minimizing the risk of aortic dissection and cardiac valve regurgitation/insufficiency with the use of ciprofloxacin

03.12.2021 1795

Information letter for healthcare professionals on the risk of aortic aneurysm and dissection, as well as heart valve regurgitation/insufficiency, associated with systemic or inhaled use of fluoroquinolones. Contains recommendations on benefit/risk assessment, risk factors, and reporting of adverse reactions. generated automatically

Systemic and inhaled fluoroquinolones: warning about a new risk of heart valve regurgitation/insufficiency

01.12.2021 1888

An information letter for healthcare professionals on the increased risk of heart valve regurgitation and insufficiency with systemic or inhaled use of fluoroquinolones, with a list of risk groups and recommendations for benefit-risk assessment. compiled automatically

Letter to healthcare professionals regarding the medicinal product VIZKEW, solution for injection, 120 mg/ml

Fabrazyme®

Gilenya* (fingolimod)

“Important safety information on the use of IRINOTECAN MEDAC (irinotecan hydrochloride): Drug toxicity in patients with reduced activity of UGT1A1

Checklist for a physician prescribing micafungin

Information letter for healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders associated with the use of retinoids

EDUCATIONAL MATERIALS CONTROLFLEX (thiocolchicoside): Information for healthcare professionals on the risk of genotoxicity

Letter to healthcare professionals: Important information on the potential risk of genotoxicity with the use of the medicinal product CONTROLFLEX

Important information on minimizing the risk of aortic dissection and cardiac valve regurgitation/insufficiency with the use of ciprofloxacin

Systemic and inhaled fluoroquinolones: warning about a new risk of heart valve regurgitation/insufficiency

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration